May. 14 at 7:41 PM
$OPK
1. In‑vivo CAR‑T generation in mice and non‑human primates
The platform uses:
Bispecific CD3×CD28 antibodies
Conjugated to lipid nanoparticles (LNPs)
Carrying mRNA encoding a CAR
This allows the body’s own T‑cells to be activated, transfected, and converted into CAR‑T cells inside the patient.
This is the core ModeX platform.
2. Deep systemic B‑cell depletion
The abstract explicitly states depletion in:
Blood
Spleen
Bone marrow
Lymph nodes
This is the key efficacy readout for CD19‑directed CAR‑T.
If you see deep B‑cell depletion across multiple compartments, the platform is working.
3. Repeat dosing without lymphodepletion
Because the CAR is delivered via mRNA, not viral vectors:
You can dose repeatedly
You do not need chemotherapy preconditioning
You can expand memory T‑cells over time
This is a major differentiator vs. traditional CAR‑T.
